Loading...
Loading...
NEW YORK, NY · CIK 0001263508
New positions
15
Added to
21
Trimmed
17
Exited
11
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $22.67B across 115 positions in their Q2 2020 SEC 13F filing (period ending 2020-06-30). The top 10 positions account for 85.2% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | $8.03B | 35.43% | -5.6% |
| 2 | INCYIncyte Corporation | $3.33B | 14.67% | +0.1% |
| 3 | ONCBeiGene, Ltd. | $2.22B | 9.79% | - |
| 4 | ACADACADIA Pharmaceuticals Inc. | $2.03B | 8.96% | - |
| 5 | ALXNAlexion Pharmaceuticals, Inc. | $983.31M | 4.34% | - |
| 6 | BMRNBioMarin Pharmaceutical Inc. | $936.06M | 4.13% | - |
| 7 | KODKodiak Sciences Inc. | $626.41M | 2.76% | - |
| 8 | ASNDUSDAscendis Pharma A/S | $501.42M | 2.21% | - |
| 9 | NVTA1EURInvitae Corporation | $358.97M | 1.58% | +30.2% |
| 10 | MYOKEURMyoKardia, Inc. | $305.73M | 1.35% | +78.3% |
| Stock | Value | Shares |
|---|---|---|
| Forma Therapeutics Holdings, Inc. | $92.98M | 2,000,000 |
| ADCTADC Therapeutics SA | $78.99M | 1,687,500 |
| ALTAltimmune, Inc. | $22.57M | 2,107,600 |
| NVAXNovavax, Inc. | $20.12M | 241,376 |
| VXRTVaxart, Inc. | $14.51M | 1,639,121 |
| XENEXenon Pharmaceuticals Inc. | $10.02M | 799,102 |
| BNRBurning Rock Biotech Limited | $6.75M | 250,000 |
| TARAProtara Therapeutics, Inc. | $5.85M | 199,671 |
| LEGNLegend Biotech Corporation | $5.75M | 135,000 |
| CBAYUSDCymaBay Therapeutics, Inc. | $5.32M | 1,522,792 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.